Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Updated results from CARTITUDE-1

Yi Lin • 11 Jun 2022
EHA 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some updated results from a 27-month follow-up of the CARTITUDE-1 trial (NCT03548207), investigating the use of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory (R/R) myeloma, drawing focus on the impressive response rates observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Yi Lin

Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5
1:41
Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5
Yi Lin • 4 Sep 2025
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma
2:02
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma
Yi Lin • 4 Sep 2025
Guidance for junior researchers entering the cellular therapy field
1:55
Guidance for junior researchers entering the cellular therapy field
Yi Lin • 4 Sep 2025
The transformative effect of immunotherapies on the treatment landscape of DLBCL
3:06
The transformative effect of immunotherapies on the treatment landscape of DLBCL
Yi Lin • 4 Sep 2025

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Yi Lin • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Yi Lin • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Yi Lin • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Yi Lin • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals